Company intelligence / Profile preview

Granza Bio

San Francisco, California, United Statesgranzabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Granza Bio is developing a novel therapeutic delivery platform inspired by the immune system’s "attack particles," aiming to deliver targeted therapies that kill cancer cells while sparing healthy tissue. Their preclinical data show efficacy in multiple solid tumor types including brain and ovarian cancers. The company is currently at the seed funding stage with ongoing research and development.[2][4]

Therapeutic areas: Oncology
Modalities: Engineered attack particles (protein-based)RNAProteinsGenetic modifiers[1][3][4]
Industry: Biotech

Beyond the preview

Go deeper on Granza Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granza Bio.

Explore the full profile